"Well we are half way through 2016 and the milestones on p26 don't seem to be very far along."

13 more trading days to go for end of month. If you count the RVX-297 publication, along with the imminent licensing deal and renal trial, we may have 2 or 3 more checks off the list by end of June or early Q3.

"Critical issues like the BETonMACE trial update were not addressed in detail."

They're in the recruiting stage right now, so not much to update on. What were you looking for? Taiwan should be active by end of 2016 and status of US sites/FDA were discussed on slide 21. Will have safety data for over 1000 BETonMACE patients at time of FDA meeting at end of year.

"Does anyone know if he took questions? I sure hope some other posters can give me a positive spin on Don's pathetic performance on this update. I did think that 2016 could be a break through year but it has been a disappointment from the start."

He did take some questions at the end. You can listen to them in the archived webcast. Slide 21 was very informative and it is exciting that the renal program will be launching shortly. However, it is unclear if it is a Phase 1 with a new molecule or Phase 2 with RVX-208/apabetalone. Probably the latter, but not clear.

BearDownAZ